NASDAQ / LIVE COMPANY INTELLIGENCE

Mirum Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERMIRM
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / MIRM COVERAGE

What’s moving Mirum Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript

The story matters when it changes Mirum Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Mirum Pharmaceuticals, Inc. v. Annora Pharma Private Limited

Mirum Pharmaceuticals, Inc. v. Annora Pharma Private Limited

The story matters when it changes Mirum Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates

Investors are testing whether Mirum Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates

Investors are testing whether Mirum Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest MIRM filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-04 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-25 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-18 · Period 2026-06-15SEC ↗8-KMaterial company eventFiled 2026-05-18 · Period 2026-05-12SEC ↗8-KMaterial company eventFiled 2026-05-06 · Period 2026-05-06SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-23 · Period 2025-12-31SEC ↗144Official SEC filingFiled 2026-08-03SEC ↗
EARNINGS / QUARTERLY TRACKER

Mirum Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.